<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-002881
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20070702
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20070706
<DATE-OF-FILING-DATE-CHANGE>20070706
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>07967289
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w36880e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) July&nbsp;2, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NOVAVAX, INC.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046</B></TD>
</TR>
<TR valign="bottom">
    <TD colspan="2" nowrap align="center" valign="top"><B>(State or
other jurisdiction of <br>
 incorporation or</B> <B>organization)</B>
</TD>

    <TD align="center" valign="top"><B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(I.R.S. Employer Identification No.)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>9920 Belward Campus Drive</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Rockville, Maryland</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Zip Code)</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(Address of principal executive offices)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Registrant&#146;s telephone
number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(Former name or former address, if changed since last report.)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</B>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On July&nbsp;2, 2007, the Board of Directors of Novavax, Inc. (the &#147;Company&#148;) appointed Len Stigliano as
its Vice President, Chief Financial Officer and Treasurer. Mr.&nbsp;Stigliano had been serving as
Interim Chief Financial Officer of the Company since April&nbsp;9, 2007 pursuant to an agreement with
Tatum, LLC, an executive search firm where Mr.&nbsp;Stigliano was a partner. The Company will pay a fee
to Tatum, LLC not to exceed $117,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to an employment agreement (the &#147;Agreement:&#148;) between the Company and Mr.&nbsp;Stigliano dated
July&nbsp;2, 2007, Mr.&nbsp;Stigliano will receive an annual compensation of $250,000. Mr.&nbsp;Stigliano will
participate in the Company&#146;s bonus program and is eligible for a maximum bonus of $100,000 per
year. On the date of the Agreement, the Company granted Mr.&nbsp;Stigliano options to acquire 225,000
shares of common stock of the Company, which vest over three years. Mr.&nbsp;Stigliano is entitled to
participate in the Company&#146;s Amended and Restated Change in Control Benefits Plan, which provides
that he receive twelve months severance in the event that the executive is terminated in connection
with a change in control of the Company. Finally, the Company will reimburse Mr.&nbsp;Stigliano for
travel and lodging expenses incurred in connection with his commute to the Company&#146;s headquarters.
This reimbursement is limited to $25,000 per year for a maximum of three years. The Company has
also agreed to reimburse Mr.&nbsp;Stigliano for an additional amount equal to the state and federal
income taxes imposed on the travel and lodging expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the Agreement is attached to this report as Exhibit&nbsp;10.1 and is incorporated herein by
reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company issued a press release announcing the appointment of Mr.&nbsp;Stigliano as its permanent
Chief Financial Officer on July&nbsp;5, 2007. A copy of the release is furnished with this report as
Exhibit&nbsp;99.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibits</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement between Novavax, Inc. and Len Stigliano dated July&nbsp;2, 2007</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued by Novavax, Inc. dated July&nbsp;5, 2007</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="63%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Novavax, Inc.<br>
(Registrant)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">July&nbsp;6, 2007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Len Stigliano</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Len Stigliano</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" nowrap align="left" valign="top">Vice President, Chief Financial Officer and</TD>

    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>w36880exv10w1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="RIGHT" style="font-size: 10pt; margin-top: 18pt"><B>
Exhibit 10.1
</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EMPLOYMENT AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Employment Agreement (this &#147;Agreement&#148;) is dated as of July&nbsp;2, 2007, between Novavax,
Inc., a Delaware corporation (the &#147;Company&#148;) having its principal office at 9920 Belward Campus
Drive, Rockville, MD 20850 and Len Stigliano, an individual (&#147;Executive&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and Executive hereby agree as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Employment</B>. The Company hereby employs Executive and Executive hereby accepts employment as
Vice President and Chief Financial Officer and Treasurer upon the terms and conditions
hereinafter set forth. As used throughout this Agreement, &#147;Company&#148; shall mean and include any
and all of its present and future subsidiaries and any and all subsidiaries of a subsidiary.
Executive warrants and represents that he is free to enter into and perform this Agreement and
is not subject to any employment, confidentiality, non-competition or other agreement which
prohibits, restricts, or would be breached by either his acceptance or his performance of this
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Duties</B>. During the Term (as hereinafter defined), Executive shall devote his full business
time, attention and energies to the performance of services as Vice President, Chief Financial
Officer and Treasurer of Novavax, Inc., performing such services, assuming such
responsibilities and exercising such authority as are set forth in the Bylaws of the Company
for such offices and assuming such other duties and responsibilities as prescribed by the
President and Chief Executive Officer (the &#147;CEO&#148; and Board of Directors. Executive agrees to
perform his services faithfully and to the best of his ability and to carry out the policies
and directives of the Company. Notwithstanding the foregoing, it shall not be a violation of
this Agreement for the Executive to serve as a director, trustee, officer, or consultant to a
charitable or non-profit entity; provided that such service does not adversely affect
Executive&#146;s ability to perform his obligations hereunder. Executive agrees to take no action
which is in bad faith and prejudicial to the interests of the Company during his employment
hereunder. Notwithstanding the location where Executive shall be based, as set forth in this
Agreement, he also may be required from time to time to perform duties hereunder for
reasonably short periods of time outside of said area.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Term</B>. The term of this Agreement shall be a period beginning on July&nbsp;2, 2007 and continuing
until July&nbsp;1, 2008, unless earlier terminated pursuant to Section&nbsp;7 hereof (the &#147;Term&#148;) and
shall be renewable annually on the terms set forth herein upon agreement of the Company and
Executive of the term of such renewal and the initial base compensation applicable to the
renewal term. The parties acknowledge that the employment hereunder is employment at will.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Compensation</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Base Compensation</B>. For all Executive&#146;s services and covenants under this
Agreement, the Company shall pay Executive at an annual rate of $250,000, subject to
review by the CEO of the Company and the Board of Directors (or any committee of the
Board of Directors authorized to review and evaluate executive
compensation) when compensation is reviewed after the completion of the audit with
respect to the 2007 fiscal year (in accordance with the management processes), and
each fiscal year thereafter and payable in accordance with the Company&#146;s payroll
policy as constituted from time to time. The Company may withhold from any amounts
payable under this Agreement all required federal, state, city or other taxes and
all other deductions as may be required pursuant to any law or government regulation
or ruling.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bonus Program</B>. Executive shall be eligible to participate in the Company&#146;s
performance and incentive bonus program applicable to senior executives. Eligibility
for bonuses and amounts to be paid each year are determined by the President and CEO
and the Board of Directors (or any committee of the Board of Directors authorized to
make that determination) based on the Company&#146;s and Executive&#146;s performance. Under the
existing bonus program, Executive would be eligible for a maximum bonus of 40% of
Executive&#146;s base salary during the year to which the bonus relates. The bonus may be
paid out partly in cash and partly in shares of restricted stock at the discretion of
the Board of Directors. Any bonus paid in 2007 will be prorated. The time spent as
Interim CFO will be included in calculation of the prorated bonus for 2007.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Stock Awards</B>. Subject to approval by the Board of Directors (or any committee
of the Board of Directors authorized to make that determination), the Company will
grant Executive (a)&nbsp;stock options to purchase 225,000 shares of the Company&#146;s Common
Stock ($.01 par value) at an exercise price equal to the closing price of the Company&#146;s
Common Stock on the later of Executive&#146;s date of hire or the date of such Board of
Directors&#146; approval. This stock award will vest as to one-third of the options on each
of the first three (3)&nbsp;anniversaries of Executive&#146;s date of employment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Executive will be eligible for additional stock awards based upon performance
subject to the approval of the President and CEO and the Board of Directors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reimbursable Expenses</B>. Executive shall be entitled to reimbursement for reasonable expenses
incurred by him in connection with the performance of his duties hereunder in accordance with
such procedures and policies as the Company has heretofore or may hereafter establish. In
addition, the Company will reimburse Executive for transportation and lodging expenses
incurred in his commute from Blue Bell, PA to Rockville, MD. The Company agrees to reimburse
up to $25,000 per year during the initial Term and, if the Agreement is so renewed, during
each year of the first two renewal periods. In addition to the reimbursable expenses, the
Company shall reimburse Executive for an additional amount (the &#147;Gross-Up Payment&#148;) equal to
the state and federal income taxes imposed on the reimbursable expenses (exclusive of any
income taxes which may be imposed on the Gross-Up Payment).</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Benefits</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Executive shall be entitled to four weeks of paid vacation time calculated and
administered in accordance with Company policies in effect from time to time. The
Executive shall be entitled to all other benefits associated with normal full time
employment in accordance with Company policies. A copy of the Company&#146;s current
benefits plans are attached hereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the approval of the Board of Directors, Executive shall be entitled
to participate in the Company&#146;s Amended and Restated Change of Control Severance
Benefit Plan, as amended July&nbsp;26, 2006 (the &#147;Change of Control Plan&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Termination of Employment</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding any other provision of this Agreement, Executive&#146;s employment
may be terminated, without such action constituting a breach of this Agreement:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By the Company, for &#147;Cause,&#148; as defined in Section 7(b) below;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By the Company, upon 30&nbsp;days&#146; notice to Executive, if he should
be prevented by illness, accident or other disability (mental or physical) from
discharging his duties hereunder for one or more periods totaling three
consecutive months during any twelve-month period;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By the event of Executive&#146;s death during the Term.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Cause&#148; shall mean (i)&nbsp;Executive&#146;s willful failure or refusal to perform in all
material respects the services required of him hereby, (ii)&nbsp;Executive&#146;s willful failure
or refusal to carry out any proper and material direction by the President and CEO or
Board of Directors with respect to the services to be rendered by him hereunder or the
manner of rendering such services, (iii)&nbsp;Executive&#146;s willful misconduct or gross
negligence in the performance of his duties hereunder, (iv)&nbsp;Executive&#146;s commission of
an act of fraud, embezzlement or theft or a felony involving moral turpitude, (v)
Executive&#146;s use or disclosure of Confidential Information (as defined in Section&nbsp;10 of
this Agreement), other than for the benefit of the Company in the course of rendering
services to the Company or (vi)&nbsp;Executive&#146;s engagement in any activity prohibited by
Section&nbsp;11 of this Agreement. For purposes of this Section&nbsp;7, the Company shall be
required to provide Executive a specific written warning with regard to any occurrence
of subsections 7(b) (i), (ii)&nbsp;and (iii)&nbsp;above, which warning shall include a statement
of corrective actions and a 15&nbsp;day period for the Executive to respond to and implement
such actions, prior to any termination of employment by the Company pursuant to Section
7(a) (i)&nbsp;above.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Separation Pay</B>. Subject to Executive&#146;s execution and delivery to the Company of the
Company&#146;s standard form of Separation and Release Agreement, the Company shall pay Executive a
lump sum amount equal to six months of Executive&#146;s then effective salary (the &#147;Separation
Pay&#148;), upon the Company&#146;s termination of Executive&#146;s employment by the Company without Cause,
during the Term. Separation Pay shall be subject to
withholding of all applicable federal, state and local taxes and any other deductions
required by applicable law. In the event of Executive&#146;s termination pursuant to Section
7(a)(ii), the Company&#146;s obligation to pay further compensation hereunder shall cease after
the expiration of the 30&nbsp;day notice. In the event of Executive&#146;s death, the Company&#146;s
obligation to pay further compensation hereunder shall cease forthwith, except that
Executive&#146;s legal representative shall be entitled to receive his fixed compensation for the
period up to the last day of the month in which such death shall have occurred.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>All Business to be Property of the Company; Assignment of Intellectual Property</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Executive agrees that any and all presently existing business of the Company
and all business developed by him or any other employee of the Company including
without limitation all contracts, fees, commissions, compensation, records, customer or
client lists, agreements and any other incident of any business developed, earned or
carried on by Executive for the Company is and shall be the exclusive property of the
Company, and (where applicable) shall be payable directly to the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Executive hereby acknowledges that any plan, method, data, know-how, research,
information, procedure, development, invention, improvement, modification, discovery,
design, process, work of authorship, documentation, formula, technique, trade secret or
intellectual property right whatsoever or any interest therein whether patentable or
non-patentable, patents and applications therefor, trademarks and applications therefor
or copyrights and applications therefor (herein sometimes collectively referred to as
&#147;Intellectual Property&#148;) made, conceived, created, invested, developed, reduced to
practice and/or acquired by Executive solely or jointly with others during the Term is
the sole and exclusive property of the Company, as work for hire, and that he has no
personal right in any such Intellectual Property. Executive hereby grants to the
Company (without any separate remuneration or compensation other than that received by
him from time to time in the course of his employment) his entire right, title and
interest throughout the world in and to, all Intellectual Property, which is made,
conceived, created, invested, developed, reduced to practice and/or acquired by him
solely or jointly with others during the Term.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Confidentiality</B>. Executive acknowledges his obligation of confidentiality with respect to all
proprietary, confidential and non-public information of the Company, including all
Intellectual Property. Executive shall not, either during the Term or thereafter, use for any
purpose other than the furtherance of the Company&#146;s business, or disclose to any person other
than a person with a need to know such confidential, proprietary or non-public information for
the furtherance of the Company&#146;s business who is obligated to maintain the confidentiality of
such information, any information concerning any Intellectual Property, or other confidential,
proprietary or non-public information of the Company, whether Executive has such information
in his memory or such information is embodied in writing or other tangible form. All originals
and copies of any of the foregoing, however and whenever produced, shall be the sole property
of the Company. Upon the termination of Executive&#146;s employment in any manner or for any
reason, Executive shall
promptly surrender to the Company all copies of any of the foregoing, together with any
documents, materials, data, information and equipment belonging to or relating to the
Company&#146;s business and in his possession, custody or control, and Executive shall not
thereafter retain or deliver to any other person any of the foregoing or any summary or
memorandum thereof.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Non-Competition Covenant</B>. As the Executive has been granted options to purchase stock in the
Company and as such has a financial interest in the success of the Company&#146;s business and as
Executive recognizes that the Company would be substantially injured by Executive competing
with the Company, Executive agrees and warrants that within the United States, he will not,
unless acting with the Company&#146;s express prior written consent, directly or indirectly, while
an employee of the Company and during the Non-Competition Period, as defined below, own,
operate, join, control, participate in, or be connected as an officer, director, employee,
partner, stockholder, consultant or otherwise, with any business or entity which competes with
the business of the Company (or its successors or assigns) as such business is now constituted
(currently defined as a human vaccine development business) or as it may be constituted at any
time during the Term of this Agreement; provided, however, that Executive may own, and
exercise rights with respect to, less than one percent of the equity of a publicly traded
company. The &#147;Non-Competition Period&#148; shall be a period of one year following termination of
employment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Non-Solicitation Agreement</B>. Executive agrees and covenants that he will not, unless acting
with the Company&#146;s express written consent, directly or indirectly, during the Term of this
Agreement or during the Non-Competition Period (as defined in Section&nbsp;11 above) solicit,
entice or attempt to entice away any customer, officer, employee, consultant, proposed
customer, vendor, supplier, proposed vendor or supplier or person or entity or person
providing or proposed to provide research and/or development services to, on behalf of or with
the Company. Executive agrees and covenants that he will not, unless acting with the
Company&#146;s express written consent, directly or indirectly, during the Term of this Agreement
or thereafter interfere with the Company&#146;s relationships or proposed relationships with any
customer, officer, employee, consultant, proposed customer, vendor, supplier, proposed vendor
or supplier or person or entity or person providing or proposed to provide research and/or
development services to, on behalf of or with the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Notices</B>. All notices and other communications hereunder shall be in writing and shall be
deemed to have been given on actual receipt after having been delivered by hand, mailed by
first class mail, postage prepaid, or sent by Federal Express or similar overnight delivery
services, as follows: (a)&nbsp;if to Executive, at the address shown at the head of this Agreement,
or to such other person(s) or address(es) as Executive shall have furnished to the Company in
writing and, if to the Company, to it at the address set forth in the preamble hereto with a
copy to Jennifer Miller, Esq., Ballard Spahr Andrews &#038; Ingersoll LLP, 1735 Market Street,
51<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> Floor, Philadelphia, PA 19103, or to such other person(s) or address(es) as
the Company shall have furnished to Executive in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Assignability</B>. In the event of a change of control (as defined in the Company&#146;s Change of
Control Plan), the terms of this Agreement shall inure to the benefit of, and be assumed by,
the acquiring person (as defined in the Company&#146;s Change of Control Plan).
This Agreement shall not be assignable by Executive, but it shall be binding upon, and to
the extent provided in Section&nbsp;8 shall inure to the benefit of, his heirs, executors,
administrators and legal representatives.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">15.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Entire Agreement</B>. This Agreement contains the entire agreement between the Company and
Executive with respect to the subject matter hereof and there have been no oral or other prior
agreements of any kind whatsoever as a condition precedent or inducement to the signing of
this Agreement or otherwise concerning this Agreement or the subject matter hereof.
Notwithstanding the foregoing, Executive acknowledges that he is required as a condition to
continued employment, to comply at all times, with the Company&#146;s policies affecting employees,
including the Company&#146;s published Code of Ethics, as in effect from time to time.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Equitable Relief</B>. Executive recognizes and agrees that the Company&#146;s remedy at law for any
breach of the provisions of Sections&nbsp;9, 10, 11 or 12 hereof would be inadequate, and he agrees
that for breach of such provisions, the Company shall, in addition to such other remedies as
may be available to it at law or in equity or as provided in this Agreement, be entitled to
injunctive relief and to enforce its rights by an action for specific performance. Should
Executive engage in any activities prohibited by this Agreement, he agrees to pay over to the
Company all compensation, remuneration or monies or property of any sort received in
connection with such activities; such payment shall not impair any rights or remedies of the
Company or obligations or liabilities of Executive which such parties may have under this
Agreement or applicable law.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Amendments</B>. This Agreement may not be amended, nor shall any change, waiver, modification,
consent or discharge be effected except by written instrument executed by the Company and
Executive.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">18.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Severability</B>. If any part of any term or provision of this Agreement shall be held or deemed
to be invalid, inoperative or unenforceable to any extent by a court of competent
jurisdiction, such circumstances shall in no way affect any other term or provision of this
Agreement, the application of such term or provision in any other circumstances, or the
validity or enforceability of this Agreement. Executive agrees that the restrictions set
forth in Sections&nbsp;11 and 12 above (including, but not limited to, the geographical scope and
time period of restrictions) are fair and reasonable and are reasonably required for the
protection of the interests of the Company and its affiliates. In the event that any
provision of Section&nbsp;11 or 12 relating to time period and/or areas of restriction shall be
declared by a court of competent jurisdiction to exceed the maximum time period or areas such
court deems reasonable and enforceable, said time period and/or areas of restriction shall be
deemed to become and thereafter be the maximum time period and/or areas which such court deems
reasonable and enforceable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">19.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Paragraph&nbsp;Headings</B>. The paragraph headings used in this Agreement are included solely for
convenience and shall not affect, or be used in connection with, the interpretation hereof.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">20.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Governing Law</B>. This Agreement shall be governed by and construed and enforced in accordance
with the law of the State of Maryland, without regard to the principles of conflict of laws
thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">21.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Resolution of Disputes</B>. With the exception of proceedings for equitable relief brought
pursuant to Section&nbsp;16 of this Agreement, any disputes arising under or in connection with
this Agreement including, without limitation, any assertion by any party hereto that the other
party has breached any provision of this Agreement, shall be resolved by arbitration, to be
conducted in Philadelphia, Pennsylvania, in accordance with the rules and procedures of the
American Arbitration Association. The parties shall bear equally the cost of such arbitration,
excluding attorneys&#146; fees and disbursements which shall be borne solely by the party incurring
the same; provided, however, that if the arbitrator rules in favor of Executive, Company shall
be solely responsible for the payment of all costs, fees and expenses (including without
limitation Executive&#146;s reasonable attorneys&#146; fees and disbursements) of such arbitration. The
provisions of this Section&nbsp;21 shall survive the termination for any reason of the Term
(whether such termination is by the Company, by Executive or upon the expiration of the Term).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">22.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Survival</B>. Sections&nbsp;8 through 21 shall survive the expiration or earlier termination of this
Agreement, for the period and to the extent specified therein.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed or caused to be executed under seal this
Agreement as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">NOVAVAX, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;SEAL&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rahul Singhvi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rahul Singhvi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">/s/ Len Stigliano<BR>
Len Stigliano</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>w36880exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="RIGHT" style="font-size: 10pt; margin-top: 18pt"><B>
Exhibit 99.1
</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="w36880w3688000.gif" alt="(NOVAVAX LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tricia Richardson</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Novavax, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">240-268-2031</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOVAVAX NAMES LEN STIGLIANO CHIEF FINANCIAL OFFICER</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Rockville, MD., July&nbsp;5, 2007, Novavax, Inc. (Nasdaq: NVAX) said today that Len Stigliano has been
appointed Vice President, Chief Financial Officer and Treasurer, effective July&nbsp;2, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Stigliano has been acting as Interim Chief Financial Officer since April&nbsp;9, 2007, through an
arrangement with Tatum LLC, a national executive service firm where he was a financial partner.
Prior to his tenure at Tatum, Len spent over 30&nbsp;years in various financial and general management
roles in life sciences.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I am extraordinarily pleased to welcome Len to Novavax&#146;s senior management team,&#148; said Novavax
President and Chief Executive Officer Dr.&nbsp;Rahul Singhvi. &#147;Len&#146;s depth of knowledge in financial,
general management and drug development is outstanding. He also brings important expertise in
negotiations of business transactions, fund raising, human resources, and facilities management.
He has proven his talent and skills as interim CFO, and I am confident he will add tremendous value
in the exciting times ahead for our company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I am pleased to join the Novavax team on a permanent basis,&#148; Mr.&nbsp;Stigliano said. &#147;I am impressed
with Novavax&#146;s focus and commitment to becoming a premier vaccine company, and with the enthusiasm
and talent in the Company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We have been impressed by Len in his role as interim CFO and are looking forward to working with
him on permanent basis. He is a seasoned finance and business professional,&#148; said Michael McManus,
a member of Novavax&#146;s Board of Directors and chairman of the board&#146;s audit committee. &#147;His
expertise, insights and discipline will help ensure Novavax delivers on its milestones.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A certified public accountant, Mr.&nbsp;Stigliano has held roles as a CFO in several public companies as
well as general management positions in diagnostics and most recently as President-Global
Operations of a clinical research organization where he supervised over 800 professionals globally.
He has also raised over $250&nbsp;million in equity transactions, joint ventures and management buyouts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Stigliano also holds a BA from Rutgers University and an MBA from Pace University.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novavax, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt">Novavax Inc. is committed to leading the global fight against infectious disease by creating novel,
highly potent vaccines that are safer and more effective than current preventive options. Using
the company&#146;s proprietary virus-like particle (VLP)&nbsp;and Novasome<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> adjuvant technologies,
Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other
viral diseases. Novavax&#146;s particulate vaccines closely match disease-causing viruses while lacking
the genetic material to cause disease, which provides potential for greater immune protection at
lower doses than current vaccines. With an exclusive portable manufacturing system that allows for
rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health
needs.</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>w36880w3688000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w36880w3688000.gif
M1TE&.#EA)@$N`.8``!M*>?+U]/S\^1U0@QQ-@^SR],O9XQQ-BO7Y^9BOQ/7X
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MAOO[^_W]_OO\]-CG[8.DP2U,<1I*A!U#BD]PE?W]_?[^_O___R'Y!```````
M+``````F`2X```?_@!2"@X13'Q0%&B)?##8(*`R1#%(:`08+A9A)&DLH`I\Z
M-0(;=`Q@(2ZE(U8=.7%:#@<'*RMZ#5H87D)83CP,=$TB-0$(.FH\:V8D%E:$
MA%M.`:4V-I(,`GU]`D0H-B)+:DL%6UN#6U.8%'"_(B0I*9\U-0PCY<Z#4P8(
M+G9BD=1]7"Q!<B6=.4'0!&19(L`&"QN?^D"P08<.A!VE&"B04.Z<LP\;-I!0
M($"2#CA?7$A8,&6*LY93KFC0X`@!"P'A+)QK>0]=@!`:P`BH*$"'CD@N4'$4
MY-*<%9#7&*`0X\?/'S)8LVHMHR1/@A8Z1-`1``8%!`@H4!`1(,&+DJP`_^*>
M"9"J9"0_`EP0$2$"08L/$3*H4`)`SP$`88XH)F#BR9,P`P"443%AQH("-\44
MU2'`G0(G;@@#T"I9RX)2/]94DY3M4S<(`GJ(B4!&CU8]!,J\J+$![[M/)7D4
M\%%&:]8R90#@T,>`AX"++/J($/##"G*X'+)B&")E.@O5$:]]$B.-@8@`0;`2
MP`T@LH<'/#;L@"=)@!D>,G(8OTTF1X$`;Z"`P`](I`"!#&<H45QQ9,15!@=E
M1%``'"6]808#V?3!`'D%9"#:;0!X%<`U&E)EE2PHIGC`$8?Q80!%(KB@P7QG
M=2."!54`4,2.!Y@PP!DME%(2-0RXX(((3?!@0/\'%ZA`P``#Q!##"@V@2,L*
M,330P`H@Q$```1ZP\0(,%JQAI!U+I-!##07DP)@)LE!)10,$=+!&``I0)%Y&
MKME`0A]T6!!$G(;1<H`#5MA@!AT"P2.`&"+PL,`-6Z:(I98#.#"#!46^\\,.
M?3`B!8($@&"JE@3,XL$"+%Q#S5@ET2&"46)LT-D:7+!Q0!%31A&%"01@4,(&
M:PC`4'UV*/"`"E,604N5L@"K`A!P,)0"$DCLX,@"<FQ9Q"Q4:@G`!&,@`*@U
MDFQ00`(<F$`+G%M&`<`,,A0+G(E_:*GOOG1BJ6D+&S!`PHP&4J.:!1GHL6.X
M!``II%0VB!'0&@58$0?_5@X4$44,LG@Y0)6I-O!$ORO,TF4#9=R`QQ4V2+$$
M&!JX``<"#[`Q)2U9HEJ%#"T@0511%8D'"0_^+,#&$WJT02>P``0A`P]O&-'9
M)QB>YP,`46!Y0)4Q'&&"8@-,,(48=KR3K89]\(!`!P-$8>H188S<M1`M1.4)
MU;(N80<#9G3&`KL<'S#`$7-R\`+`YKE`=21+6'#US1N;8$*5#80!`!2)Z+!$
MFA.Q4,`8[6Y]Z<>1Y7!'P"1@8PT"4\@1Y<8-0`DL#G?\((51SS%0U1]0]N[[
M`%2LX*,*!JPC0@HLP-:-#2@,P4<,'D3_9,,!D&"##AI&0D(-$KR0AP=4R/*M
M_RS1.W:$ED?T?H0#6G)<"_1E>#$%"P,KL(--%M!`0`-9^XCT"C<80PM^\`6^
MI,`./[.++UCP`A60KG=A4,(#6L4`(I`@=9)8PP>4$+PHT,D#@AO`DX!5AAG\
M1``I^%0VVM$"+F!@`)(C0'N@%`8WW`$!(H@$<'[Q,C#\HC,MR```HN>`N!"`
M#'GX@*):`YQ2!&`,-\C:_B37'C`-(&Y)U$`2%(<-`4B!&!UP8*J`18`G^(@#
M0@B`GZ9#!U)`P`)N(4`,HB!"&2J'"7#H@1WL\!P(Z,XJ_.+7DZ!$@"X4P$]2
MZ0,1^M`-%CC/!![85]A:P(*;>+$D<"B`$)PDI9P=0/\/'CBBKWSEM2BTP5<.
MV)\<I;0C$'!@`DH,P0\0\`@Z),`6OIJ<EE;@@<,I0%;'TP$=(,*97S!`71?@
MP.`4$P8"A.$&+.N#9CY!`B)\80,2$$(9#@"";U4)!"J*@1XN,`41M*:"LB*!
M&0J0!@*X+0R0^=@1E``#<P5,/#P$@P^_0`<X&"!Z#8C>`)YPQ`P@X)[`^40;
M`Y`!#YC*,`V@PI.B!S[H"0$!!<P03I8PJA<H84M*B]T1?I4'*^R#(2((20$B
M`(`GK*`-PIN>&Z;0`CNH@8\Z[,/N.LG33A;AB@,X``<2H(`>-&$J1$@J'5!@
M`3Y\C0I4(-PD7;"#;72G"1;_>$$9W"DE?1V`8UH"I1:TP(:QAI*;W736OK)&
M!CE,06V5[(,&#,`'`'!3%OLKF1R&((U2:(8!$$@!9\P0DB<.<4H@@"K*(H!0
M%%ZP#S6@PP/RX(`8@(`6X;OL9:_4``#XP!=F".TB\Y(",3"!`]R4G/A6`(`*
MR(`!<,B0AF1EE&/V(0`=T(.4L)2U`]S@`6NXYS52MP/8PH`,ECT`015C@HTE
M-GA4X,`'>,"#2MZ-!")@P0C0,`!344%V4P+`3'F@N!JL`0%8N,$4O1;5`6CA
M`7[I1EK2HLC=!7)?PH-A$0@P@2L8H081,T-2<]A47>J+>CWH`1TTY(@$.'`6
M.6N?_QX<H((+S"`!"_C`!R[Q@`Y400MZ,%3LY'D`*I"!!C)@05IPLM(RQ.(`
M7V+,81:`@![8)1*!M0/V`*7)@#:@J[&[P0=J,)U/O`,"?F"`X]K#/Q^Y5PON
MDAP,CT"`&Q@`$I]8Y#66L($6\($,*_ANJGHT`+>.!4/9:,0.S7,%/C@K9UTB
M0P:N(`J[?`("1EB#!;I`ABG/`9YC_9JO&N`U/6SJ(9[8$!W$@`PF7```5/(=
M`1S``11OP`5)0,`'ZBI"!XR,H"KH@`5H6<EJ2"P;]KVOEG0YBP%$J``U4#%P
M2*#D*NARMP>80`M<D((D-^(.;!AS4/65/@#(H0-,:$$+X/^PANK"@04(D,`#
M'BW'?65)#R9^P#J>@SP#4!:O3SH":]$0``W<&+`'Q-XOKB`'$,@SJB9HF@4T
M`(]WT*<.1,#""5(Y)2^I@`8ST(*60ADE`BBA`RU`80J(0`=&,.`+"'#PBGQ4
M);@-E0ZTSE`C_$@B$5A!!2<C-#@Y$`$;]*"8&.K,#GCP\>^:H`U_YD`%*N`!
MQ40ADNYDPQ38<2PQ%"L+/QC#"?0%0V`-K@P)*,`&4%"`"G"`<@2/C!!&4+W.
M041U.@4D^L[W-1_!"451>,(-K%"#'P0V!=\(%!^VMMN2Z7JIT]F`!68``!/,
M"4RK[NP%DAV`:\JJ":6X)@-:,(3_3>Y/7T6H$A7T,`$#$-<&<&A!%V+QK7!'
M@0`GN$(/ED`""%3$'8(MR082H`00$%HQBN$`$%I`[X3FD`<!\,+32XPE#ZC@
M`5S`P9<\0(95>L`-!OC!YA>Y8.D$H`1\8$P8)%>Y(P#`/W6.!`IVP/%/M$`(
M9&A#E@8'@G&^:/,WOB#L]7.`2/JJS`O8P@U@R$OPM6$/+P@`7Y+`>>9MH@9P
M>(`R"3!28,VQ`7DP!I[#+BZU-5`E43@@`PJP.5*P!MH0'OB2>!&5/N[2!BJP
M`N/C`5RB!Q4@`1H@!2A024O@2&OW,>W#7PFG#6H0`!^``<+#?,#S5<8V!0'@
M@%5Q@SCH_P<[``<6D`,`<`1S,`=48"KEAR414#=+MP$V8`4<X#;08WX@0`8/
M8`,NH``*X#-IPC@,T"$>L",TY&X78`%#H4A$X`>:(0)PL`4.)%!S8`)ZP`<R
M4`,=0`:SX&.8\@(8M03H\G"X!0!/\F-4$`9T@@$+D`5@L`05@0)?@#<V8``7
M4`1S<`1/\#$&]P(6D`2T)@D-]P5IR`$4U5T@``!"4``%@`/P%%3?8@)A@`%`
ML&!*^`-WYD<0-P-B)%&1!$E*4`4&8`!R4"K[%811H`=Q0`$L8#\Y>(Q:%U&3
MV`!Z$`1HX"QXM24$H`(1(`)2T`A^8@--)3CZXB6ZICHAT`(1$/]BDC,Y,=@`
M'``#+5``M(:,-YB-CG@$;>`UW01C6)(!%A``9A!<VFAK43`GD70$XH0#`X0$
M"O`##YAR#/`!>:`P/P4E,:`%1[@$YI1U>\&#7G!X6O(K'#!!+O`!<>``8<<O
M2F``/-`=&8$A4@`'+?B',2`W`V`X9K`$1R$50E(2+!`!%P@V(A23)ID%8\@:
M`9`?0P10IG<#"[`&<``#'!`&BR<E*]):<!!;)0$<W7!-$H`&93!2$H4J1T0#
M.-!2)?8U;5!EK(*)`N"..)@O[>,Q>I`&'P!B=()W`84!(V`>$*`:M?:')_B-
MTA$"FJ0'7L=\<T(&?&`!<,`#.:26?F#_)D:P4G7G-;,0)S'@5FL@"5\0``D`
M`/P389/#`09@A4B`(3I4$BVF,#GC(SC`!#M@;MA0AI_``\LR;(1V>1,P!)=9
M`!U0!FVP-?LR+Q8@-7PB`$G``W/'F3DC3H<Q`0'P&U*A0WOC91X0`Y+C-3'P
M?"W@,@*00Y%0$?E'*0`U1P3@`Q+`"$/P:#%P=YAR`DRP!@QQD\SS!4O@3SG`
M`5#9`'`2.),()U_#,2=PA$8@!2Z0=8R9+Q\C)5\BE7B@3#\V:;BA!VA0`-_P
M$'MI@@WJEWG!!1<@94474;:7`)_@`HW`F/(I``I0`@YDCKHD.=1H`QN`-FPB
M!S\(.W0R`&0@_R$*X$.0<`TIT(@70(=4X#XQ,`!XT`)7N`,,48;8<Y[M@B6*
MT0#4B*0"PP1Y\`0A!XA("4Q2$5C:P@,?X$"(5S)Z4`:LD@)@8`?=,!9E`00@
M5&UM0`5/P`$+L`-9H`;X=`U?,`090(>[9'IYL`!P<(T(H)-?0V7,*$.8\YXZ
M9`,[0'\DL`,E,`&HY4W-`@+:!U6'%VH%X#.A0J!J^0?I\V-%$#UE4`%#*41;
M$BX_%H!PX`)*6*'=B()=1`(+<`)S(COGLP+\10$)IH=TP)C:T`-(T`(X@)^Q
MTXWHZ`/1H4-?8`-A9*6F]R1/<``X4`)%M0$LH!E&$G&>Z"6&L35R\/\!.Y!@
M2(H-VJ"9'R4E+T=E&3`"1=4'/1``0C``EQ))ED4`%8"8TH<"=E`]*]D%(J0E
M;Q8#9.`#!?`#&F`'UD46+9`&J94ECD$`^$@"/9`%^+0!D2)QI@<N')`!+6!.
M2X=\C/%G^Z("4X!=D:`9?E(@#?$7<M"%13`G[L(QU#EP92!JFY=#$&`B!1JJ
M/Q9*GL4#+?!QH)B<'+`SR``1.,*7%YJ")+`!#Q!%Q_JDNLH'(Z`&8)`"*."I
MQZ@-.M"C[82?4/*;!K5@YO$)%#`!;>-!8WL`6C`&"R@&"``I2U`#%E`!=,B-
MLJ`'ED@">E.NOX`K0E2SI$1R"A`":D`'6K3_`$Z"5S`$3FPP!I<I%?RZ`P(A
M`K/Y=5I#`')@K4'!J`6T!%<0!T4``@(Y2`"0`#AT+$/11GK&!_2:)3.K`@(H
M"HO8`AW0+D\:D`-`;@YW#2AP+=00@@&`!7FP*ZH64!T[`B%PB!5!?8RY.]_5
M/N+B`TG2`O7I-J;W8P=0!@]0`&LP'3@RMGV9@MJBDV$G3^E3"S1@`5BKM5R;
M@VOQM0R`!W*T`G&S+P3`!Q\K39^0!'"@53`UMB80A8>S!F_P"*GS!1_`!LBU
M-=-J8@O``R3`&:%'`G30`J37-C[2!I+3>)O0`PR0!4G0)L+&?5'``5W0`M60
M%D<A$`(P`A=06>(4_SQ9P@%PZP)($!)K@!9CD#&)=3X$P`$G,`*P<6Y?(`8M
MP)3\8X"ZZ@420`)24!(NP`)3<`)VMR]VIP)<P`,IB4)(X!`,H`,A@`)HX``G
M`R4`I24'H',_86Z-`+W1^P?0\S&.40L5P`,]X$\34"J=Q"4-H',(P!`X0G'E
MBPT_P`(=()(#$$F$)D=O&0#A`!",>6HZ]0``,"62^`3G$SNZQ@AT<"'88`5N
M`$.Q$SZQLW<FURI&P@`S`#Z3`RQT@@,%L'D+%A;$20<&H'O3NWPF0`8)$`"B
MD`P<Q0-;P`%O`D_SN#Y6T"KG1!0Y28=>PB*$!@`>RP.C>0T*T`+ZTV]"./_$
M+T"%`I`6DM`$:W`'Q5HR$N4CWNLGV#`63:";8&9Z'],8AF8!J;-B[R`)-8`$
M!0`$.%"':OQCJ(('!9`4=J$-\7N,?P`"`*48>%PM"A``$<`!02HEW=0&9(`&
M[BL`3;4"%NJ-*9C('>`!=.3(5%8+05``:H`\$,&8:2$Q?K"9[C(GG+QJ%Q`D
M;9061.`"(U`!D6D"'%-&-Y``+*`!VO-%<4``425'DP/,-K`0I:`#?M(#?=`!
M4':KB6$"6L`%!=(<%V0D`7`!R1P&;4AE!LLG37"V-E`";(`E'.`UA!8&><`%
M<(`$?S(27.``CAP#<Q`9<K``!T0"E<1S8I``#D#_!;HT.,$BA@RP`[;2TPHP
M!2!$S^<#0SK'%]VP.;0&*P'0`E!`P]V(,W2B<U2HLRF@A]%K%1%V/I^4QR0!
M!R/@)I72`%U290\@!5*`,#^5G+(J,#DY`&T03P.GJRNM!BX`$$FUW,S-#1G1
M!Q4])28(-U3&OZEP%N:QQPN@!`,P!]""GQ)KI#_@`B00``N`S%_#U.D3![4C
M!:D##]XI`R?`&-_E`50$!49J!\D-`9<F%@F@7CT"&5YC`BH`J/1G`TTP"M(!
MV@[`6M-]!$@7`$;@Q0&P+GUVH'.@!VAD`35@/43BMRY@`3@PL[(371V``D9P
M$?[P!49``@7`9U+"D_(2_W_-@0*/^A!K\`,57M%1,JK\9R@<>@$R<&E+``'D
M_4<%6G/GDSZO_04*(!9P\'%CQ@$K0$<$<`$2H"Y5D'A=)=(-<10.-MQC&S@2
M.P(]X`)H(0;-W=P4$2IT,`-,O0(<P"M71`4`4`4(8&[5!P8B(`%JZ]T`]2OL
M::1K4@`OX(>](]0`T`%X@@`0L3=MM%)@UC5<@WE3,""_40UB00=<L*==]26[
M,@#Y&A3T(P)^I`-+C`%%$$^H-P!=,`+F+``M4`(T<`"G*#R^]0`[0-AZP@`<
M]40$`,A7],L7,%T[<.R_@`*DL`%C\+)S)(DP%#930`?7Z!#0M@$*\#G[U@`[
MXO\`@P,G'@`9J@@`+S`"?NL/BSG'2DYH0<6!3CX*GA,$JQ3L$I4;"<"#5<!V
M6>+E$-$'8Z`%49`^)K@U5_X!Y#V\:\[<+-`;7[`&-/!C/K)]A%-(++`$(NH/
M`L!':]/=3]AD)(<`>!T`=]"+,9:IR9;(4\V'7-"+7]4^'J#"^9B84SGS3?#9
M"SH`H+0_=9@'!D"GD#`1VJ``0Q`$>K",3]H`-S`%S2H`1@!%0PH9SS)G'=[K
MVE`#LSWIF/($\_(?RJ9L4QD`<"#R3B<R`P5#3Z`$>-@.#<$"/`!Q7#`!9<`U
MG\08OU(Y]8R.1R@=2;;0.?@'Z\[D[GZV+H``!G`"4=+_)9)#!1X@9,ZC[TW;
M$"7Q`1=P*5KR!(K-U?!%?0Z14)P_SHS@2%I`G8WAF]SN`1W``CU=FMO)`EQP
M`@*]3-9L`6%!,YPI/3BWPIUWQ&/13W1G;62/`31P`3@P_,0__'QP`1C07&WP
M,3U"G66`!A(@!7S$J%A&,^VB+^QS&!UPUTG0`G1GH07LO04@!;Y0'W2@F2I@
MKZDY`!AP`>Y?_#C@_L)O,T&\-$$V+$4Q%*G`!>D!"&UZ100$,0<')D=1#02(
M;29:"2TB2RP,?IF:FYE_'D='#4<#!WH57WTB`DLI!3,`!R`$)C$K!QPS0WP'
M#3$QO003+0(V`AM#&0=%OPU4_T\F)@-0+2Y+2\4"V=K;/2X("WJTT,PQ13</
M"`(I#`S9#"0(%CX$*S$#`Z`$;`8"(@%=ACP40J0"G0`&*>PLH:/#QA`Y`@<T
M\,#K2)@!`"X2T,.Q2"F!14`4B:+GP`H344P0D#/%!AAB.RZ1(,$%A\E?'LH1
MH"$#B90[?.XAN@<B3XET7^BP4\?`0A<]!#ST\J4(XX!"'#D2`$!FP`H0(*(<
MH6*B48,R$1`LZ=:D!H(('%;(+:*G09LR*CB$B6*K0<D8)BZ4Z*-C!PI.B/UX
M`B6*E*FD[>ST0%`"8I$&#5#*4@&$1EU?P(21L$&"1PLA'#SR(@MJ``89+C1T
MF[DJ!?\)%R126`,CQ14OS(PP'_`0QP`<$@O;';1=8`R'1/=HW4I`9\.5&X@H
MUM+#IP2<&@QZ@%E(HL"#,H`'>'#P2Y$BN?#A`SX0!42]!G)CB&V`JT46.C:P
ML`,#4HA00`=Z@("3,@>P844($(QQ`S0''#*`'CX4P(,4?=#1AP"%H3#&"=GU
M8I]*!.!7RUPG1>4(:)A%`\P%(R31PQ)?H/``&WJ<9$*%#81Q0@(5`-!&$;04
MX<$341``A04N(.$"'73XT4<?B2T6RBBEG+*4#G;8T`(>*AP@D68FE)$&!I_]
M$D,P+9```0D;;/"`"B5AM@(HHW`000`U9-'#;0)(04(V,Y'_$$(61EC!!C,-
M!-<+&3Y8P`,)?2QUD#H*R#`!`?=<)-=.`<`QAA*(5/B5'AVT\,.42VB`XQI<
M9`#`21-1U,`]`_R8Z@&S0",L:/3$P&<#`$Q`P4(VV+!#-DLH\,%S,7B0DUP>
MO/`#"T)\0LHA3W```P(DB+`!*CKT`$<+`"US%2(QA!'&CW)!TXA)C8":8D0-
M.#"5`PFL(844:Q@P`2G1A)$?`!%88(`<#8"0I`<#_*)%!'"$<)`(5F*)F):-
M=?D%`U="B\`0.70E40SV#2?05*'%"<&538Q0!<Q[,N:!$@_8`(<+8HAAQM`;
M"!UT$C9\X`4'F`'7P!-Z4)''`RRL_R$`$>Q<^6$*2+#0@0I7O7L`%1P8($$7
M9?`2BRT8?+#!$E/^H$$*(KQ51DYEY=KT5/=9>ZQPO/@2`Q54-#`<!T)L8`,*
M*$"0@@`DN-7%'E0(-/@*!&`0P!TW$&"17P<`D($%.[@@0!_%I)`$"T`HX<%]
M3>N!SXJ0O@X[9E>EV&\O*[AF`1S650$`%?8,,.\*`-!00``MC*$"65$H*54T
M'%@!O"979OG)EHZ=XJ$8)']!0@L+G%!(BGP=`A7,;XH&P<@B&#$&`-$,`,(H
M$JU`=@0CM%`G'#RP`0,"Q`(66&!$'(@*9IZ`&2H,H`P^D,`.?@`!.BSA(,H1
M076<<`$R//_A"/0`@1X8)B$".+`742A#!PJP@3Z8;@T*6`(##'`!`#P#++]P
M`%1Z59:$R8M7O&I$79X`&JGL2@5<8($`!8`$$C#@"W"@0)FD`L+M;"$!`#A"
M-%)T@#)@`0$L<&&S?K`$,4B`!EV9!0@'X`!@.0(1YQL('`OQ+IPTK4(`F(0%
M:#`\7B@0(Q/@PJ5^\)9;K:`7>WN"'!:``$SX@63:8PR7'D.'H*&@#U^(E@4Z
M````%.((AT`$9D#3/IG520`]..,]"'"_>T2L""NX01<>X(0"P.$2-N!!`*ZP
MA1>P8183Z47A%N@`1BJ@B0Q8@@X80(=^:%`$(9@!&2)E.%L0``?_09!(%,YD
M`@=\P`@\L"`$!$3!%ZC`<R80">9<<X%VQN&=[8RG/.4)ME`$DX$`>`$+FZD`
MX&W`"`7`@1ZVE[\]^``'\BJ+4-@@@0`Q8`,L0(`"MF6%<]XC)2#,7#SCT,X)
MS%.>&+@`&ZQE1(HD(@,?B```RO$+!@V@('#X`@+60(<S5N@(.'S"`)Y`!AH8
M@`>9@N3'$J'0[HVL#T'KD`!V@(`1L`$`O=J/+X@G.%D(8P,>^I`W8'`"6"#I
M*N4`P0$<```5>$$($7@`#!Z0@!E4P0T9X<NNF@$JS```"@5@06Y2X#@,,O.O
M/;#"#0;0AE0=P@%:B)18CF`F'!1@!VO8_X``YN2"&LA@I)ZK#PC:$`8V`*$$
MH`VM:$=;`B:4-@<<R-M5,$.`&QC`!E^($DT])(`$<&``40!2.53@`(N`$A(<
M0(,&8*M!&ZS!"`$H0!`<\30JK&";GB6M=$-KV@2<P(BZ\X4*,D`BCV1F!45P
M(!I*!5$>,.`;$^!`%%+2M'MX``T6:`$FLP8^,70"5[Q2206D@)A,T8$%#^#`
M$U;0!OQ%RIZ+@-,&2"8&R*VA>7A"$F"(M[=\Z8$,9,@*%8^E+X%X``!IN`,"
MFID-))Q.:RCN@P308,A4X0J4ZXU"##@PAA:T0(GM6$(6`M`!):%PO2;@`!Y$
M8-_$&)D=6%#!!_]-<!%2'"`,0F`!#W1P069^R`)R,%(1//+&P0%G3RP!`PF4
MTDP1B``."^@5C+;L@1F8V,A6`M_BJL&#.P3!D\V`T:X8)!49(X\&):B!"#+U
M!3'``0Y8F%`8N!@-$R`O`@7X@@Y,QP`4"+`3];O*;0%0@2STEYDBD$`&F/8T
M>?WP'D^@`IQLT`<BJ`,)"FA!`2)P75-+)%?64@0HPL"G421R<"8@'@=R<(<6
M,$`5)%M'BE'\#50U(B)`7+(#,"!B"(!/'1H(`1?<@+][,&8?(X,S)ZY4G0+P
M@0!;%LZ6]9`'+JQ!!'8X\8<0@`85'`E8JW2O5)X``#048&[:2)<+).#_@XSP
MBJ1LF,(2/)88(F0*!69`5`ONM!'#P0B(0JG6#<8P8A&0K`\!Y($%7I&91L>H
MM0^@0PW\*M0_:-%>O>)T$CY-!W,9P`T)U"FO#<RR8!0``3MP=:PTH(#D6J$*
M%9\K&QW@`+"$1"0>V;)\,M,(`&BA`Q)@01),AT$!B&'96N-!`28``&N!RKU!
M#!T>"F`##;(C!3MH`8OGT.UG```/+6@"P\7MA^I0"04P4,(@%#$0_J!A".F0
MMP#@``2R.Y?)IVZ:`_+`\1!8`P([`(,=)JZ"/:E'*@XHPPP"$&XC/_PPA!$`
M`JY@JYV"@G!4L(BI?^0!+P9`%>JP3=#J9($<_Y3A?EJLQ[ST<((/Q)0=3ZR2
M8L0R%Y-P&@XT5T4+S%DQ7]1'QBR3Q1E^C@0BB&$M&B!Z`0I@`"A@((&ZHP*0
M,[U*S(!%01[(RPTR``,)''/K2D'^Q\$^O@@H@7?U$A:@H'%,0"Y?H#@"M`9,
MT#GI=$@>4#@G8`!A9`9\IPGY1S)#<`$)0@4:L2\GL``MT&!:PP`&Q&(K(BPF
MHB##=@5OLP0B$"!+0`)#\!0A42W*X``?&$9[QPG9P#BN5@U?$``/`%6\$Q;U
M42^TP!]=8`$]@`0_D`)0:#H>L@$\L`"?XAX*90)%0`8Y(('(IQ2=L"LF108$
M4`85(%\HUC'LX`T?4/]#UN)BAJ,,''`&+;`#/7`E"+$$=H`$3!4/,-`%;J`$
M"91][241K<%*A0,`')`'7O``,M`"2)`$23!9^I<U8.=""L`%619'Z)8P!$`&
M7=`"I'&`$<4`!Y(V]'`X]W"&+'`0*;8)8(=\+=`!S[$5`\`!9,@!9:!/^X=4
M<?<`G9,J=(0?F%,&Z)!,+O""+)`"7P",'K`'MO"&98`&,G`N.[@)D]4LF;(*
MT7(';'`WCI`?H60F&"$'QI<$&N"$<[(*&`1%"5`&P1(-SY`('/`"%I!,#?%Q
M?G`![\11[S0!'1``K[@)=H``!9``?,"/_:B0'94#`2")^Y=[HV%I"(``=P#_
M`T%P`7GA1N=S%9Y$``Z@`B=``QU0`J+X#E`(`8R#`I4XD)E@&[/H41\53U5@
M!0C``]D0(`A@`T[@`_X83QY%`XRT`9CBDAUSB2Q@`%T`E!/P3G)P`3GP`1['
M`$F%-%<@!/SH3O,4!SD@`X/F`I1F`ZWP`F<@3PLY!0@@!1M`@48V62A`9B"B
M`RDPBUX`3S/9436V!DO@A!0$`=O0#W`0`&C`-#'`;U#!)RK0*ED`=Y>$)3(@
M`9`I`18@`8\9`D;I!\;``@$@`YP9F9(YF9T).8-V)42`-<J!2C%X@`4P`A3P
M`!V0!D&``Q<04A=``T$`!0^P`%Q@`;;T'9.HDBO)_Y)^9925U1N<>9S(V9FD
MUV"354!QAYQW@)P2T`(!\%=&>8E7@AL%0)F>*0$E$)T!(%E4^74"T`1-L)V/
M"9GIV9D28(U?<"-+L`,I``<2,`)#<)R>V0(\D(R.E!B6&%3;L)V1B9_J>9R!
MZ4(D\`.&(32E"2+&4#!\,$V@`BST`PDWL``H$&LZV'<NJ!10Q``0H`:7*0(C
M$TYSLE=TX`(WP@(MD`(W,IJE:9I(=3K,1"4;8"4"0`<(8&/,4Y$^"EE&L`:+
M$S1B($#ZIP[Q]I_9HPG9T`,T6G,-X7;M4"!*$0"'\C@1]81+L`$B``'-(@`N
M\%!TD`3+!HO8"09JX`)&@/\$XZ$*2&!C-\E@0<-,7U"G9,:ER/$XF4*BJD!B
M.B``*,`"6%4#)+848<H.,@1G5T*DE:8U=J`!:M`#/<`UXJ$&6[H48T8E[."7
M,=J@5`8'`L`"5I!E5%`*PU$+;\(28*2/X6&I=!"D.[EP:;@)=7)LUL`*.[`#
M%M2$-H8$LL(0IU.:['!MY?*"#_50//`%D=4L=7(N&[`&8(`$TFH;[%!).5IS
MJP`&8+`.O;AW6I<%:H`*-4=D[H`"+CIH8A``9'1!!90$X]$.'H<"Z4("$:4`
M\K:DF8"=J?"@R-$/#+`#"J``W9!_*'`0%=EV15H="`@!)'-L'F)F-0H@=-`$
M+I#_!<FH%"C0#6O``RSP$G"&?-G8+&^Y!B1@!`)`LA64#52B-5S:!"382*W6
MJ>HP/F;P!0?)`2(!+T1U!`"``U<@0-FC')78K3M(,D1@!D%UI-E8L,M&!$<Y
M@E_W2'B8-0[7BZ[F#LST=5^78MJ`?$;)3%A;H\,ZIWYEI$JK?TEU$(NCI'NG
MKU/K7W"ILMW:+%]()1?HM4<YM$MQM]E`I*>CJ&B;5-DS@GI;K9F"5%';J1TC
M`B10I.,C!&6P94_G1U1`!H=G7LIGIEI3@:8WJYP[;IY;@66*/?JJN9=HNF[;
MMJ5+NMB)NJ.;KZF[N:Q[NI_KNI_[NGSGK\4@`C*0`7JP_R++@!F+@`N_8SJ@
M*[NU.[O7>+NARW>XZ[:N>YVQBZ]/"W;1&[K0J[S9"[NMF[S<B[S.>YD?JQ39
M4#?ELQ&Z$B.8,R0MD`0<@[K>J[SQ^[W+V[G8N[KT^[S3J[K=F[_2V[_5N[T!
M++Z<B[OB9L"`Z[4UX#5Y8428D2!MT%H?(*3'2[W)2\`%W+P'_+^TZ[_W.[W7
M"[X"/,+[&\(6S+P:;+_@*VYB4+#9D`(A$`(KQ@&$Z!>AI`<^RP(57+^BF\(9
MO,(;_,$=/,!"G+HFS+]#3,(@K+T8'+X^W%]-S`DMG`V$$0)@@``?@`,$T`8@
ML"M>40\Q0"DM\`=D3,:<4,9HG$G&:FS&F[#&;IS&9_S&<!S';`QG:,QW=UR[
M>6S'98S'?2QN>\RY@9PE<NS&'U/(=:P)B&S&9A"C'[($*-`"3!`!E%S)EAP!
%6!<(`#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
